These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38361930)

  • 1. Combination treatment with anti-HER2 therapeutic antibody RC48, PD-1 inhibitor, radiotherapy, and granulocyte macrophage-colony stimulating factor (GM-CSF) in patient with metastatic gastric cancer: a case report.
    Liu Z; Wang F; Zhang Y; Lu J; Yang Y
    Front Immunol; 2024; 15():1321946. PubMed ID: 38361930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study.
    Kong Y; Zhao X; Xu M; Pan J; Ma Y; Zou L; Peng Q; Zhang J; Su C; Xu Z; Zhou W; Peng Y; Yang J; Zhou C; Li Y; Guo Q; Chen G; Wu H; Xing P; Zhang L
    Front Immunol; 2022; 13():952066. PubMed ID: 35874780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PRaG 3.0 therapy for human epidermal growth factor receptor 2-positive metastatic pancreatic ductal adenocarcinoma: A case report.
    Kong YH; Xu ML; Zhang JJ; Chen GQ; Hong ZH; Zhang H; Dai XX; Ma YF; Zhao XR; Zhang CY; Chen RZ; Xing PF; Zhang LY
    World J Gastroenterol; 2024 Mar; 30(9):1237-1249. PubMed ID: 38577174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II Clinical Study of PRaG Regimen Combined With Intraperitoneal Infusion of PD-1 Inhibitor for Advanced Refractory Solid Tumors With Cancerous Ascites (PRaG4.0P Study).
    Xu Y; Kong Y; Ma Y; Xu M; Yang J; Zhang J; Chen R; Chen G; Hong Z; Zhao X; Zhang C; Xing P; Zhang L; Zhao P
    Technol Cancer Res Treat; 2024; 23():15330338241264169. PubMed ID: 39051686
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Babiker H; Brana I; Mahadevan D; Owonikoko T; Calvo E; Rischin D; Moreno V; Papadopoulos KP; Crittenden M; Formenti S; Giralt J; Garrido P; Soria A; Hervás-Morón A; Mohan KK; Fury M; Lowy I; Mathias M; Feng M; Li J; Stankevich E
    Oncologist; 2021 Sep; 26(9):e1508-e1513. PubMed ID: 33942954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma.
    Porth I; Hirsch D; Ceribas Y; Weidner P; Weichert W; Götze TO; Perner S; Luley K; Heyer CM; de la Torre C; Hofheinz RD; Lorenzen S; Gaiser T
    Eur J Cancer; 2023 Apr; 183():119-130. PubMed ID: 36848831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study.
    Nie C; Xu W; Guo Y; Gao X; Lv H; Chen B; Wang J; Liu Y; Zhao J; Wang S; He Y; Chen X
    BMC Cancer; 2023 Dec; 23(1):1239. PubMed ID: 38102538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PRaG Therapy of Refractory Metastatic Gastric Cancer: A Case Report.
    Xu H; Hong Z; Xu M; Kong Y; Ma Y; Shan C; Xing P; Zhang L
    Front Immunol; 2022; 13():926740. PubMed ID: 35874658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
    Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
    BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case report: Long response to PD-1 blockade after failure of trastuzumab plus chemotherapy in advanced Epstein-Barr virus-associated gastric cancer.
    Pan Y; Lu L; Liu H; Chen D; Han N; Yao R; Wang X; Gao X; Yu J; Chen L; Zhou F; Hao G; Lu Y; Li M; He G; Kang F; Li Z; Tang Y; Zhang J; Wei L; Nie Y
    Front Immunol; 2022; 13():1003859. PubMed ID: 36353623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Supplementary granulocyte macrophage colony-stimulating factor to chemotherapy and programmed death-ligand 1 blockade decreases local recurrence after surgery in bladder cancer.
    Miyake M; Hori S; Ohnishi S; Toritsuka M; Fujii T; Shimizu T; Owari T; Morizawa Y; Gotoh D; Itami Y; Nakai Y; Anai S; Torimoto K; Tanaka N; Fujimoto K
    Cancer Sci; 2019 Oct; 110(10):3315-3327. PubMed ID: 31385407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The gut microbiome affects response of treatments in HER2-negative advanced gastric cancer.
    Han Z; Cheng S; Dai D; Kou Y; Zhang X; Li F; Yin X; Ji J; Zhang Z; Wang X; Zhu N; Zhang Q; Tan Y; Guo X; Shen L; Peng Z
    Clin Transl Med; 2023 Jul; 13(7):e1312. PubMed ID: 37381590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma.
    Partyka S; Dumas P; Ajani J
    Cancer; 1999 Jun; 85(11):2336-9. PubMed ID: 10357402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hopes and failures in front-line advanced HER2-positive gastric cancer therapy.
    Kong F; Yao Y; Deng R; Li X; Jia Y
    Anticancer Drugs; 2021 Aug; 32(7):675-680. PubMed ID: 33929993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.
    Tabernero J; Hoff PM; Shen L; Ohtsu A; Shah MA; Cheng K; Song C; Wu H; Eng-Wong J; Kim K; Kang YK
    Lancet Oncol; 2018 Oct; 19(10):1372-1384. PubMed ID: 30217672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma.
    Moehler M; Högner A; Wagner AD; Obermannova R; Alsina M; Thuss-Patience P; van Laarhoven H; Smyth E
    Eur J Cancer; 2022 Nov; 176():13-29. PubMed ID: 36183651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting HER2 in metastatic gastroesophageal adenocarcinomas: What is new?
    Coutzac C; Funk-Debleds P; Cattey-Javouhey A; Desseigne F; Guibert P; Marolleau P; Rochefort P; de la Fouchardière C
    Bull Cancer; 2023 May; 110(5):552-559. PubMed ID: 36229267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.
    O'Shaughnessy JA; Denicoff AM; Venzon DJ; Danforth D; Pierce LJ; Frame JN; Bastian A; Ghosh B; Goldspiel B; Miller L
    Ann Oncol; 1994 Oct; 5(8):709-16. PubMed ID: 7826903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients.
    Cheng YC; Valero V; Davis ML; Green MC; Gonzalez-Angulo AM; Theriault RL; Murray JL; Hortobagyi GN; Ueno NT
    Br J Cancer; 2010 Oct; 103(9):1331-4. PubMed ID: 20877352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the efficacy and safety of a precise thymalfasin-regulated PRaG regimen for advanced refractory solid tumours: protocol for the open-label, prospective, multicentre study (PRaG5.0 study).
    Kong Y; Chen R; Xu M; Zhang J; Chen G; Hong Z; Zhang H; Dai X; Ma Y; Zhao X; Peng Y; Zhang C; Xing P; Zhang L
    BMJ Open; 2024 Mar; 14(3):e075642. PubMed ID: 38458816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.